OncoFusion will develop therapies for genetically defined cancers, and, more specifically, against targets related to recurrent gene fusions. Gene fusions are often the “driver mutation” in the cancers in which they are found.

While the initial focus will be on the four targets (Bromodomain inhibitors, ERG inhibitors, EZH2-EED inhibitors, MMSET/NSD 2 inhibitors), OncoFusion has the potential to pursue additional gene fusion related targets in the future, especially in the context of ongoing cancer genomics discoveries made at the University of Michigan or The Cancer Genome Atlas (TCGA), at large.